Ingevity (NGVT) Q4 2025 earnings summary

Executive summary

• Completed sale of North Charleston crude tall oil refinery and most of the Performance Chemicals Industrial Specialties product line, reducing portfolio volatility and enhancing profitability.

• Initiated strategic alternatives for Advanced Polymer Technologies (APT) and Road Markings after a portfolio review, with updates expected before year-end.

• Achieved strong execution globally, with adjusted EBITDA margin rising for the third consecutive year and robust cash flow generation.

• Generated $274 million in free cash flow, enabling net leverage improvement to 2.6x and $56 million in share repurchases.

• Significant non-cash impairments in APT and Road Markings impacted GAAP results.

Financial highlights

• 2025 net sales were $1.3 billion, down 8% year-over-year; Performance Materials sales flat, Performance Chemicals down due to repositioning.

• GAAP net loss of $167 million, including $337 million in pre-tax special charges, mainly goodwill and asset impairments.

• Adjusted EBITDA up nearly 10% to $398 million, margin expanded to 31.9%.

• Adjusted gross profit margin improved to 43.1% for FY 2025.

• Adjusted diluted EPS increased to $4.55.

Outlook and guidance

• 2026 adjusted EPS expected between $4.08–$5.20; net sales $1.1–$1.2 billion; adjusted EBITDA $380–$400 million.

• Free cash flow guidance of $225–$250 million, excluding $95 million in litigation payments; net leverage targeted at 2x–2.5x.

• $300 million in share buybacks planned through 2027.

• Stranded costs from divested Industrial Specialties expected to be eliminated by year-end.

• No meaningful recovery in global economies or automotive industry assumed.